NanoPac®

DRUG3 trials

Sponsors

NanOlogy, LLC

Conditions

Adenocarcinoma of the ProstateLocally Advanced Pancreatic AdenocarcinomaPancreatic Mucinous-Cystic Neoplasm

Phase 2

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

CompletedNCT03077685

NanOlogy, LLCLocally Advanced Pancreatic Adenocarcinoma

Start: 2017-12-01End: 2023-03-15Updated: 2024-06-24

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

CompletedNCT03077659

NanOlogy, LLCAdenocarcinoma of the Prostate

Start: 2017-09-06End: 2018-10-04Updated: 2019-08-20

Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

CompletedNCT03188991

NanOlogy, LLCPancreatic Mucinous-Cystic Neoplasm

Start: 2017-09-29End: 2020-06-29Updated: 2021-06-14

Related Papers

Abstract B004: EUS guided local administration of large surface area microparticle paclitaxel with neoadjuvant chemotherapy in locally advanced pancreatic cancer: A single center experience

Cancer Research2024-01-16

Abstract A048: Enhancing the immune response in locally advanced pancreatic cancer (LAPC) with intratumoral endoscopic ultrasound-guided fine needle injection of large surface area microparticle paclitaxel (LSAM-PTX)

Cancer Research2024-01-16

Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: Insights from an expanded access protocol.

2024-01-114 citations

Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.

Journal of Clinical Oncology2023-06-011 citations